Cargando…

An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure

Edoxaban and its low-abundance, active metabolite M4 are substrates of P-glycoprotein (P-gp; MDR1) and organic anion transporter protein 1B1 (OATP1B1), respectively, and pharmacological inhibitors of P-gp and OATP1B1 can affect edoxaban and M4 pharmacokinetics (PK). In this integrated pharmacogenomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vandell, A G, Lee, J, Shi, M, Rubets, I, Brown, K S, Walker, J R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817390/ https://www.ncbi.nlm.nih.gov/pubmed/27897269 http://dx.doi.org/10.1038/tpj.2016.82

Ejemplares similares

Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban
por: Han, Ji Min, et al.
Publicado: (2023)

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022)

Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021)

Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1
por: Shchulkin, Aleksey V., et al.
Publicado: (2023)

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Pharmacogenomic-guided clozapine administration based on HLA-DQB1, HLA-B and SLCO1B3-SLCO1B7 variants: an effectiveness and cost-effectiveness analysis
por: Ninomiya, Kohei, et al.
Publicado: (2022)

SLCO1B1 Polymorphisms and Statin-Induced Myopathy
por: Stewart, Alison
Publicado: (2013)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China
por: Liu, Jiebo, et al.
Publicado: (2013)

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
por: Aquilante, Christina L, et al.
Publicado: (2008)

Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children
por: Li, Qian, et al.
Publicado: (2019)

Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T > C Polymorphism
por: Zeng, Weiwei, et al.
Publicado: (2022)

Prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with coronary heart disease in Xinjiang, China
por: Wang, Tingting, et al.
Publicado: (2021)

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects
por: Liu, Yue, et al.
Publicado: (2021)

Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report
por: Dagli-Hernandez, Carolina, et al.
Publicado: (2021)

SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population
por: Rattanacheeworn, Punyabhorn, et al.
Publicado: (2020)

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations
por: Sychev, Dmitrij Alekseevitch, et al.
Publicado: (2017)

Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia
por: Wagner, Jonathan B., et al.
Publicado: (2020)

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
por: Fujiwara, Yutaka, et al.
Publicado: (2016)

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin
por: Park, Jin-Woo, et al.
Publicado: (2022)

Interaction Effects of AFB1 and MC-LR Co-exposure with Polymorphism of Metabolic Genes on Liver Damage: focusing on SLCO1B1 and GSTP1
por: Yang, Xiaohong, et al.
Publicado: (2017)

Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report
por: Cha, Yu-Jung, et al.
Publicado: (2017)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
por: Taylor, Zachary L., et al.
Publicado: (2021)

Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population
por: Hubáček, Jaroslav A., et al.
Publicado: (2015)

Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans
por: Grapci, A Daka, et al.
Publicado: (2015)

The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia
por: Sychev, Dmitrij Alekseevitch, et al.
Publicado: (2016)

Genetic Variations and Frequencies of the Two Functional Single Nucleotide Polymorphisms of SLCO1B1 in the Thai Population
por: Na nakorn, Chalitpon, et al.
Publicado: (2020)

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients
por: Fajac, A, et al.
Publicado: (2010)

Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
por: Yagishita, Hironobu, et al.
Publicado: (2022)

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users
por: Jansen, Marleen E., et al.
Publicado: (2023)

Effects of ABCB1, UGT1A1, and UGT1A9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects
por: Sun, Lu‐Ning, et al.
Publicado: (2020)

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?
por: Kim, Choon Ok, et al.
Publicado: (2017)

The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
por: Sun, Ruipu, et al.
Publicado: (2020)

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
por: Mugosa, Snezana, et al.
Publicado: (2021)

Impact of SLCO1B3 Polymorphisms on Clinical Outcomes in Lung Allograft Recipients Receiving Mycophenolic Acid
por: Tague, Laneshia K., et al.
Publicado: (2019)

SLCO1B1 genetic variation and hormone therapy in menopausal women
por: Moyer, Ann M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p2dfgv58d29dq12u7u1c0si39q